In Vivo Predictive Dissolution and Biopharmaceutic-Based In Silico Model to Explain Bioequivalence Results of Valsartan, a Biopharmaceutics Classification System Class IV Drug

In Vivo Predictive Dissolution and Biopharmaceutic-Based In Silico Model to Explain Bioequivalence Results of Valsartan, a Biopharmaceutics Classification System Class IV Drug

The purpose of this study was to predict the in vivo bioequivalence (BE) outcome of valsartan (VALS, BCS class IV) from three oral-fixed combination products with hydrochlorothiazide (HCTZ, BCS class III) (<i>Co-Diovan<sup>®</sup> Forte</i> as reference and two generic formul...

Full description

Bibliographic Details
Main Authors: Isabel Gonzalez-Alvarez, Alejandro Ruiz-Picazo, Ruben Selles-Talavera, Andres Figueroa-Campos, Virginia Merino, Marival Bermejo, Marta Gonzalez-Alvarez
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:Pharmaceutics
Subjects:
gastrointestinal simulator
in vitro dissolution
weak acid
dissolution modeling
Online Access:https://www.mdpi.com/1999-4923/16/3/390

Internet

https://www.mdpi.com/1999-4923/16/3/390

Similar Items